Louis G. Lange - 06 Mar 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Director
Issuer ticker: NAMS
Reported as of: 06 Mar 2026
Net transaction value: -$828,950
SEC form: 4
Accepted by SEC: 10 Mar 2026, 20:58:01 UTC
Prior SEC filing: 09 Jan 2026
Next SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange

Key filing fact

Louis G. Lange filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 10 Mar 2026.

Key facts

This page summarizes Louis G. Lange's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2026, 20:58.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: -$828,950.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001238401 Primary reporting owner

LANGE LOUIS G

Relationship: Director
Address: C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
Signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange
Signature date: 10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Sale

Transaction value: $828,950
Shares: -28,186
Change %: -100%
Price: $29.41
Shares after: 0
Date: 06 Mar 2026
Ownership: See footnote
Footnotes: F1, F2

NAMS transaction

Ordinary Shares

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +44,619
Change %: +431%
Price: $11.50^*
Shares after: 54,979
Date: 09 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAMS transaction Derivative

Warrant (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -44,619
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 44,619
Exercise price: $11.50

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Footnote F2

The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.